Research Papers:
NOMO-1 gene is deleted in early-onset colorectal cancer
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2308 views | HTML 3082 views | ?
Abstract
José Perea1,2, Juan Luis García3, Jessica Pérez3, Daniel Rueda2,4, María Arriba2, Yolanda Rodríguez5, Miguel Urioste6,7, Rogelio González-Sarmiento3
1Surgery Department, University Hospital 12 de Octubre, Madrid, Spain
2Digestive Cancer Research Group, 12 de Octubre Research Institute, Madrid, Spain
3Department of Medicine, Molecular Medicine Unit, Biomedical Research Institute of Salamanca (IBSAL), Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca, SACYL, CSIC, Salamanca, Spain
4Molecular Biology Laboratory, University Hospital 12 de Octubre, Madrid, Spain
5Pathology Department, University Hospital 12 de Octubre, Madrid, Spain
6Familial Cancer Clinical Unit, Spanish National Cancer Centre (CNIO), Madrid, Spain
7Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain
Correspondence to:
José Perea, email: [email protected]
Keywords: early-onset colorectal cancer, NOMO-1, nodal pathway, array comparative genomic hybridization, 16p13.12-p13.11
Received: December 09, 2016 Accepted: February 07, 2017 Published: February 18, 2017
ABSTRACT
To characterize clinical features of a recurrent alteration in 16p13.12-p13.11 in Colorectal Cancer (CRC), mainly in Early-onset subgroup (EOCRC), and to assess the status of NOMO1, a gene located in that region, we analyzed differential clinicopathological, familial and molecular features of CRC subsets with and without alterations in the 16p13.12-p13.11, in global and EOCRC groups. We confirmed the region by fluorescence in-situ hybridization, and Quantitative Real-Time PCR analyzed the status of NOMO1 in different age-of-onset and Microsatellite Instability (MSI)-status CRC subsets. Both age-of-onset subsets were subsequently extended to further confirm NOMO1 gene changes. 16p13.12-p13.11 alterations were observed in 23.3% of CRCs, and was detected more frequently in EOCRC (33.3%) than in late-onset CRC (16.3%). The group with deletion in 16p showed a higher frequency of females and left-colon locations; a better prognosis; and higher Chromosomal Instability. Within the primary EOCRC population, 34 out of 34 of tumours showed a homozygous deletion in NOMO1, while in the late-onset population only 2 of the 17 tumours (11.7%) showed it. In the extended group, we found 61 out of 75 EOCRC patients (81.3%) with homozygous deletion and 7 patients (9.3%) with heterozygous deletion of NOMO1; moreover, in the new 50 late-onset patients, the proportions of deletions decreased. Microsatellite-Stable (MSS) EOCRC showed a very high proportion of homozygous loss of NOMO1 (54 of 59 cases, 91.5%), while the deletion was observed in only 7 out of 16 MSI cases. Deletion of NOMO1 is a molecular marker predominantly associated with EOCRC, particularly MSS subtypes.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15478